First iPSC- Islet Transplantation in Humans- Proceed with Caution
For the first time, a group of scientists from China successfully performed islet transplantation using iPSCs (induced pluripotent stem cells) in one patient. They made iPSCs from the fat cells of the patients using chemicals instead of the conventional way of using Yamanaka factors. They successfully tested these human iPSCs-derived islets on monkeys before using […]
O for Osteosarcoma- Part II
The future of osteosarcoma therapy is centered on innovative clinical trial designs that prioritize progression-free survival and the identification of potentially effective agents, such as regorafenib and cabozantinib. These trials aim to explore targeted combinations in patients with tumors that have been genomically and immunologically characterized. Recent advances in genetic sequencing have uncovered significant complexity […]
Wegovy®: Expanding Benefits for Obesity-Related Heart Failure with Preserved Ejection Fraction
Introduction Obesity-related heart failure with preserved ejection fraction (HFpEF) presents a significant health challenge, particularly in those with obesity and type 2 diabetes. Wegovy® (semaglutide 2.4 mg), a once-weekly subcutaneous injection, is now at the forefront of an important advancement. Recently, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a […]
Recent FDA Approvals pack Double punches against Niemann-Pick disease type C
Rare diseases, affecting fewer than 200,000 people in the U.S., pose significant challenges due to their low prevalence. According to the NIH, there are over 7,000 known rare diseases, each with unique symptoms and treatments. For example, cystic fibrosis, a genetic disease affecting the lungs, often goes misdiagnosed. The lack of large patient populations hinders […]
Transparent mice are here – Not a science fiction, but a reality.
Scientists at Stanford University have made live mice transparent, easing biomedical research and saving their lives. They used an FDA-approved food coloring dye called tartrazine, which makes the mice’s skin transparent. They used this dye on the mouse brain, abdomen, and muscle for imaging. Below is the figure of the mouse’s abdomen before and after […]
Nanotechnology: Revolutionizing Diabetes Treatment and Diagnostics
The increasing global prevalence of diabetes demands innovative solutions beyond traditional treatments, which often struggle with high costs and limited efficacy. Nanotechnology, a rapidly evolving field, offers groundbreaking possibilities in managing diabetes, providing more targeted, effective, and cost-efficient interventions. Image Source: Vinoth Khandelwal Nanotechnology in Diabetes Management Nanomedicine involves the use of nanoparticles (NPs), whose […]
O for Osteosarcoma – Part I
Osteosarcoma is a rare malignancy. Annually, approximately 1,000 new osteosarcoma cases are identified in the United States. Approximately fifty percent of these cases involve children and adolescents. Most osteosarcomas manifest in children, adolescents, and young adults aged 10 to 30. Adolescents are the most frequently impacted demographic, although individuals of any age may acquire osteosarcoma. […]
Once-Weekly Insulins Show Promise in Simplifying Diabetes Management
Introduction Managing type 2 diabetes with insulin therapy presents challenges, particularly with daily injections. Recently, new clinical studies have emerged evaluating once-weekly insulin options that aim to reduce the burden of daily injections while maintaining effective blood sugar control. These innovative treatments, including once-weekly icodec (Awiqli, Novo Nordisk) and insulin efsitora alfa (efsitora, Eli Lilly), […]
N for Narcolepsy- Part II
Narcolepsy is a central condition that causes people to be too sleepy during the day. Narcolepsy management is symptomatic; currently, there are no disease-modifying treatments available. Many individuals with narcolepsy find that tiredness and cataplexy significantly affect daily living, therefore influencing relationships, school, employment, and social life. Most patients need pharmaceutical treatment, and many find […]
Precision in NSCLC Treatment: The Predictive Power of TROP2-QCS in Datopotamab Deruxtecan Therapy
Introduction The quest for more personalized and precise cancer treatments has gained momentum with the recent findings from the TROPION-Lung01 Phase III trial. This pivotal study explores the role of the TROP2-QCS biomarker in predicting clinical outcomes for patients with non-small cell lung cancer (NSCLC) undergoing treatment with datopotamab deruxtecan (Dato-DXd). The trial highlights a […]
N for Narcolepsy- Part I
Narcolepsy is a rare and chronic neurological disorder characterized by instability in sleep-wake regulation. marked by chronic excessive daytime drowsiness (EDS) and disrupted nighttime sleep. Individuals with narcolepsy experience sudden sleep attacks that may last from a few seconds to several minutes and can occur multiple times a day. The condition is thought to be […]
CAHn you do it?
Crinecerfont can improve CAH What is CAH and its cause? In response to stress, the body releases CRH (corticotropin-releasing hormone) from the hypothalamus, which signals the pituitary gland via CRF1 (corticotropin-releasing hormone receptor 1) to produce ACTH (adrenocorticotropic hormone). ACTH further stimulates the adrenal gland present over the kidney to synthesize cortisol, aldosterone, and androgens […]
M For Multiple Myeloma- Part II
There is currently no cure for multiple myeloma; however, there are numerous treatment options available to effectively manage the disease, with new ones arising from time to time. The primary objective of treatment for multiple myeloma is to Induction therapy is the standard of care for newly diagnosed multiple myeloma, and it is followed by […]
Your Face Can Predict Metabolic Disorders
A team of scientists from Beijing, China have developed a thermal face image analysis program called ThermoFace (TF) that could predict biological age and metabolic disorders with 80-90% accuracy. They trained their program on thermal and 2D visible images of 2,811 Han Chinese individuals – 1,339 females and 1,472 males. They made a face mesh, […]
M For Multiple Myeloma- Part I
Multiple Myeloma is a rare cancer that arises from plasma cells, a type of white blood cell produced in the bone marrow. These cells become malignant, proliferating uncontrollably and leading to tumor formation primarily in the bone marrow. When only a single tumor is present, the condition is called solitary plasmacytoma. When multiple tumors are […]
Redefining the Standard of Care: Lazertinib and Amivantamab for NSCLC
The FDA has approved lazertinib (Lazcluze) in combination with amivantamab-vmjw (Rybrevant) for the first-line treatment of non-small cell lung cancer with specific genetic mutations. In a significant advancement for the treatment of non-small cell lung cancer (NSCLC), the U.S. Food and Drug Administration (FDA) has granted approval to lazertinib (Lazcluze) when used in combination with […]
FDA Approves Lazertinib and Amivantamab-vmjw Combination for First-Line Treatment of EGFR-Mutant NSCLC
Introduction The U.S. Food and Drug Administration (FDA) has granted approval for the combination of lazertinib (Lazcluze) and amivantamab-vmjw (Rybrevant) as a first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring specific epidermal growth factor receptor (EGFR) mutations. This approval marks a significant advancement in the treatment landscape for […]
L for Legg-Calve-Perthes Disease- Part II
Legg-Calvé-Perthes disease (LCPD) is a pediatric hip condition characterized by interruption of the blood supply to the femoral head, leading to osteonecrosis. This condition primarily affects children between 4 and 8 years but can occur between 2 and 15 years. Various treatments, including both surgical and nonsurgical options, have been explored to manage LCPD. Despite […]
FDA Approves Neoadjuvant/Adjuvant Durvalumab for Resectable NSCLC
Introduction The U.S. Food and Drug Administration (FDA) recently approved the use of durvalumab (Imfinzi, AstraZeneca) in combination with platinum-based chemotherapy as a neoadjuvant treatment for adults with resectable non-small cell lung cancer (NSCLC). This treatment regimen is followed by durvalumab monotherapy as adjuvant therapy post-surgery. This approval is specifically for patients with tumors measuring […]
Tasty Traps: FDA and FTC Warn Against Copycat Snack Containing Delta-8 THC
FDA and FTC crack down on illegal delta-8 THC copycat snacks, protecting consumers from unregulated edibles in deceptive packaging that risks accidental ingestion, especially by children Imagine opening a yellow and orange pack of Flamin’ hot Cheetos and munching on one of those crunchy sticks. Instead of the cheesy, salty taste of nostalgia, you start […]
FDA Grants Accelerated Approval to Afamitresgene Autoleucel for Unresectable or Metastatic Synovial Sarcoma
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to afamitresgene autoleucel (TECELRA, Adaptimmune, LLC), a genetically modified autologous T cell immunotherapy. This approval targets adult patients with unresectable or metastatic synovial sarcoma, particularly those who have undergone prior chemotherapy and possess specific HLA-A alleles, with tumors expressing the melanoma-associated antigen A4 (MAGE-A4). […]
L for Legg- Calve-Perthes Disease- Part I
Legg-Calvé-Perthes Disease (LCPD) is a type of osteochondrosis affecting children, primarily between the ages of 2 and 12, with a higher incidence in those aged 5 to 6 and a greater prevalence in boys. This condition involves the degeneration and subsequent regeneration of the epiphysis, or growth end, of a bone. Specifically, LCPD impacts the […]
Let’s MASHup!!
MASH (Metabolic dysfunction associated steatohepatitis) is a severe form of non-alcoholic liver disease, previously known as NASH (Non-alcoholic steatohepatitis). It is caused by increased fat deposits and inflammation in the liver despite low alcohol consumption. This further leads to liver scarring called cirrhosis. Untreated cirrhosis causes irreversible damage to the liver leading to its failure […]
K for Kennedy Disease- Part II
Kennedy’s disease, also known as Spinal and Bulbar Muscular Atrophy (SBMA), first identified over two decades ago due to a mutation that expands a CAG trinucleotide repeat in the androgen receptor gene, results in an androgen receptor protein with an extended polyglutamine sequence. These disorders are characterized by protein aggregation, mitochondrial dysfunction, and transcriptional abnormalities. […]
FDA Expands Endometrial Cancer Indication for Dostarlimab-gxly with Chemotherapy
The Food and Drug Administration (FDA) has approved a new treatment regimen for adult patients with primary advanced or recurrent endometrial cancer (EC). This approval includes the combination of dostarlimab-gxly (Jemperli, GSK) with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly. This regimen was previously approved for patients with mismatch repair deficient (dMMR) or microsatellite instability-high […]
A Ray of Hope- Islets transplantation for T2D patients too
Islets are a group of hormone producing cells that control blood glucose levels. Islet transplantation is considered a cure for type 1 diabetes (T1D). T1D is caused by the destruction of beta cells in islets by the body’s immune system. These beta cells produce insulin that decreases blood glucose. Islet transplantation is challenging due to […]
FDA Approves Daratumumab and Hyaluronidase-fihj Combination for Multiple Myeloma
The Food and Drug Administration (FDA) has approved the combination of daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen) with bortezomib, lenalidomide, and dexamethasone for the induction and consolidation treatment of newly diagnosed multiple myeloma patients eligible for autologous stem cell transplant (ASCT). Image Source: Vinoth Khandelwal This approval was based on the results of the PERSEUS […]
K For Kennedy Disease- Part I
Kennedy Disease, also known as Spinal Bulbar Muscular Atrophy (SBMA), is a rare X-linked recessive genetic progressive neuromuscular disease that causes muscle weakness and wasting (atrophy) throughout the body. Symptoms typically begin to appear between the ages of 30 and 50, with life expectancy being nearly normal. Males with the inherited gene usually develop symptoms, […]
J for Juvenile CLN3 Disease- Part II
Juvenile CLN3 disease, also known as Batten disease, currently has no cure, so specialized symptom management and therapy are crucial for maintaining the quality of life for affected children, young people, and their families. Comprehensive support for parents, siblings, and extended family members is essential. Therapeutic approaches to Batten disease ranges from – Enzyme Replacement […]
Slimmer Days Ahead? Roche’s New Obesity Drug Shows Potential
Roche’s oral GLP-1 receptor agonist demonstrates significant weight loss in Phase I study. The global prevalence of obesity has surged dramatically over the past half century, driving a corresponding increase in pharmaceutical development within this therapeutic area. This week, Roche introduced a new treatment option, marking a significant advancement in the management of obesity. Facts […]